培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析

《培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析【摘要】目的观察培菲康治疗前后肠易激综合征(IBS)患者肠道相关益生菌群的变化。方法选取符合罗马Ⅲ标准的IBS患者60例及年龄、性别相匹配的对照人群20人，IBS患者包括腹泻型、便秘型、混合型、未分型4种类型，再将IBS患者随机分为2亚组，治疗组予以培菲康治疗，2片，3次/d，疗程为4周，对照组予以安慰剂治疗4周，比较治疗前后患者粪便中双歧杆菌和乳杆菌数量的变化。结果腹泻型IBS患者粪便中双歧杆菌及乳杆菌含量均小于正常人群(P<0.01)，混合型IBS患者粪便中双歧

2、杆菌含量小于正常人群(P<0.01);服用培菲康4周后，患者粪便中双歧杆菌及乳杆菌含量均高于治疗前(P<0.01);以腹泻为主的IBS患者中，治疗有效者，治疗后粪便中双歧杆菌和乳杆菌含量都要少于治疗无效者(P<0.01)。结论IBS患者存在某种肠道菌群的量的变化，且外源性补充相关益生菌制剂时，患者病情的变化伴有粪便中益生菌群的变化。【关键词】肠易激综合征;益生菌;荧光定量PCR;肠道菌群　　Abstract:ObjectiveToanalysisofthefecalBifidobacteriumspp.an

3、dLactobacillusspp.inpatientswithirritablebowelsyndrome(IBS)beforeandaftertreatmentwithbifidtripleviablecapsulesfor4weeks.Methods6011participantswithIBS,asdefinedbytheRomeIIIcriteria,werecomparedwithage-andgender-matchedcontrolsubjects(n=20).TheIBSpatientsweredivide

4、dintodiarrheagroup,constipationgroup,alternatinggroupandunclassifiedgroup.Thepatientsinthediarrheaandconstipationgroupswerefurtherdividedintotreatmentgroup(2capsules,3timesdailyfor4weeks)andthecontrolgroup(placeboadministrationfor4weeks).Thevariationsinthenumberoft

5、hefecalBifidobacteriumspp.andLactobacillusspp.wereanalyzedbeforeandaftertheintervention,usingquantitativeReal-timePCR.ResultsIntheIBSpatientswithdiarrhea,theamountofBifidobacteriumspp.andLactobacillusspp.weresmallerthanthatinhealthypopulation(P<0.01),andintheIBS

6、patientsofalternatingtype,theamountofBifidobacteriumspp.wassmallerthanthatinhealthypopulation(P<0.01).4weeksafterthetreatment,theamountsofBifidobacteriumspp.andLactobacillusspp.inallpatientsincreased(P<0.01).Diarrhea-predominantIBSpatientswhohadimprovementsin

7、theSymptomSeverityScoreofIBScarriedsmalleramountsofBifidobacteriumspp.andLactobacillusspp.thanpatientswhohadnoimprovement.ConclusionTherearevariationsintheamountsofcertaingutmicrobiota,andwithexogenousreplenishmentof11agentsofprobioticmicrobiota,theconditionsofthep

8、atientsvarywiththevariationsoffecalprobioticmicrobiota.　　Keywords：irritablebowelsyndrome;probiotics;fluorescentReal-timePCR;gutmicrobiota　　肠易激综合征